277 related articles for article (PubMed ID: 12011821)
1. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
Tran A; Rey E; Pons G; Pariente-Khayat A; D'Athis P; Sallerin V; Dupont C
Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.
Andersson T; Hassall E; Lundborg P; Shepherd R; Radke M; Marcon M; Dalväg A; Martin S; Behrens R; Koletzko S; Becker M; Drouin E; Göthberg G
Am J Gastroenterol; 2000 Nov; 95(11):3101-6. PubMed ID: 11095324
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.
Heyman MB; Zhang W; Huang B; Chiu YL; Amer F; Winter HS
J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):35-40. PubMed ID: 17204950
[TBL] [Abstract][Full Text] [Related]
4. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules.
Amer F; Karol MD; Pan WJ; Griffin JS; Lukasik NL; Locke CS; Chiu YL
Clin Ther; 2004 Dec; 26(12):2076-83. PubMed ID: 15823771
[TBL] [Abstract][Full Text] [Related]
6. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
Katashima M; Yamamoto K; Sugiura M; Sawada Y; Iga T
Drug Metab Dispos; 1995 Jul; 23(7):718-23. PubMed ID: 7587960
[TBL] [Abstract][Full Text] [Related]
9. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
10. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.
Gremse DA; Donnelly JR; Kukulka MJ; Lloyd E; Lee C
Aliment Pharmacol Ther; 2004 Jun; 19(11):1211-5. PubMed ID: 15153174
[TBL] [Abstract][Full Text] [Related]
11. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
12. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
[TBL] [Abstract][Full Text] [Related]
13. Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods.
Chun AH; Erdman K; Zhang Y; Achari R; Cavanaugh JH
Clin Ther; 2000 Feb; 22(2):231-6. PubMed ID: 10743982
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.
Freston JW; Pilmer BL; Chiu YL; Wang Q; Stolle JC; Griffin JS; Lee CQ
Aliment Pharmacol Ther; 2004 May; 19(10):1111-22. PubMed ID: 15142201
[TBL] [Abstract][Full Text] [Related]
15. A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers.
Jovanović D; Kilibarda V; Maksimović M
Pharmazie; 2001 Oct; 56(10):800-2. PubMed ID: 11683127
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
Tomilo DL; Smith PF; Ogundele AB; Difrancesco R; Berenson CS; Eberhardt E; Bednarczyk E; Morse GD
Pharmacotherapy; 2006 Mar; 26(3):341-6. PubMed ID: 16503713
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
Gremse D; Winter H; Tolia V; Gunasekaran T; Pan WJ; Karol M; Chiu YL; Pilmer B; Book L
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S319-26. PubMed ID: 12607792
[TBL] [Abstract][Full Text] [Related]
19. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
Freston JW; Kukulka MJ; Lloyd E; Lee C
Aliment Pharmacol Ther; 2004 Aug; 20(4):407-11. PubMed ID: 15298634
[TBL] [Abstract][Full Text] [Related]
20. Variable omeprazole kinetics in healthy Jordanian adults.
Albsoul-Younes A; Tayyem R; Najib N
Biopharm Drug Dispos; 2005 Jul; 26(5):183-8. PubMed ID: 15906422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
